This study is testing a prediction tool that estimates 30-day survival for people with metastatic cancer (cancer that has spread to other parts of the body). The tool uses information like your lab results (white blood cell count, bilirubin, etc.), how often you've visited the emergency room, and where your cancer started. Researchers want to see if this tool can accurately identify patients who have a less than 20% chance of surviving for 30 days. You may be eligible if you are 18 or older, have metastatic cancer, and are being considered for palliative radiation therapy (treatment to relieve symptoms). The study aims to enroll 214 participants. The current recruitment status is unclear.

Study design

This is an observational study, meaning researchers will collect information without giving you a specific treatment. It is a single-arm study, involving about 214 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your survival and quality of life will be monitored at 30, 90, and 365 days after you join the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.